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ABSTRACT
Objective: The aim of this study was to evaluate for 12 months the changes of body weight using De-
pot Medroxyprogesterone Acetate (DMPA) and if these changes are related to inflammatory markers. 
Subjects and methods: Twenty women of childbearing age who chose the DMPA, without previous 
use of this method, BMI < 30 kg/m², and 17 women using IUD TCu 380A, participated in the study. 
At the baseline and after one year, changes in weight gain, body composition by the bioimpedance 
electric method, resting energy expenditure (REE) by the indirect calorimetry method, inflammatory 
markers and HOMA-IR were assessed. Results: After 12 months of evaluation, we could observe a 
significant increase in the DMPA group in weight (3,01 kg) and BMI, while the IUD group’s only signifi-
cant increase was observed in the BMI. Relative to REE there was an increase of basal metabolic rate 
(BMR) in both groups after one year. The sub-group DMPA that gained < 3 kg had increased signifi-
cant weight, BMI and body surface (BS) with respiratory quotient (RQ) reduction, while the sub-group 
that gained ≥ 3 kg had a significant increase in weight, BMI, BS, fat-free mass, fat mass, BMR, Leptin, 
HOMA-IR and waist circumference, with RQ significantly reduced. Conclusion: Our study found sig-
nificant changes in weight, body composition and metabolic profile of the population studied in the 
first 12 months of contraceptive use. These changes mainly increased body weight, leptin levels and 
HOMA-IR which can contribute to the development of some chronic complications, including obesity, 
insulin resistance and diabetes mellitus. Arch Endocrinol Metab. 2017;61(1):70-5
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INTRODUCTION
O besity is considered a serious public health problem that affects developed countries as well 
as developing ones. Globally, there are an estimated 1.5 
billion overweight adults, of which approximately 500 
million are obese (1). In Brazil, 50.8% of the population 
over 18 years old are overweight and 17.5% are obese (2). 
This complex and chronic disorder of multifactorial 
etiology is the result of positive energy balance, and 
genetic and environmental factors are involved in 
developing this metabolic disorder (3,4). In women, 
the use of hormonal contraceptives has been associated 
with weight gain and changes in body composition.
Depot medroxyprogesterone acetate (DMPA) is an 
injectable contraceptive method and in its formulation 
contains 150 mg of DMPA administered every 3 
months intramuscularly at a plasma concentration 
of approximately 1 ng/mL (5). According to the 
characteristics of contraceptive efficacy, safety and low 
cost, and ease of access due to its ready availability from 
public health systems in several countries, including 
Brazil, millions of women choose to use this method (6). 
Despite having a potential negative effect on bones, the 
most common reason for discontinuing use of DMPA is 
increased body weight (7). Most prospective studies that 
have assessed the body composition of these progestin 
users, with at least 30 months of use, show a weight gain 
associated with an increase in body fat deposits (8,9). 
In a study with HIV-infected women was evaluated 
the association between DMPA use with inflammatory 
markers (10). However, no studies in healthy 
women linking weight gain after using DMPA with 
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inflammatory markers. Therefore, the aim of this study 
was to evaluate for 12 months the changes of body 
weight using DMPA and if these changes are related to 
inflammatory markers.
SUBJECTS AND METHODS
Subjects
This was a prospective cohort study with women 
attending the family planning clinic at the Gynecology 
and Obstetrics Department, University of Campinas 
(Unicamp), Brazil. Sample size was calculated from the 
demand for women seen in the clinic who opted for 
the contraceptive DMPA method and the percentage 
of women who have segment to method use for at least 
12 months. The women were selected from February 
2011 to March 2012.
Women of childbearing age who chose the 
injectable contraceptive DMPA without previous use of 
this method, body mass index (BMI) < 30 kg/m², and 
women using the non-hormonal contraception copper 
intrauterine device (TCu 380A IUD), were invited to 
participate in the study. The participants were aged 
between 18 and 40 years. The groups were paired at 
baseline, becoming a homogeneous group in relation 
to age (± 1 year), and BMI (± 1 kg/m²).
After signing an informed consent form, they were 
interviewed to collect data and personal medical and 
family history. An administration every three months 
of 150 mg of DMPA was given and follow-up was 
maintained for one year. The women in the control 
group, TCu 380A IUD users, underwent the same 
procedures provided for inclusion into the DMPA group. 
Exclusion criteria were: women with diabetes 
mellitus (DM) type 1 or 2; those with a family history of 
diabetes; those who had fasting glucose > 100 mg/dL 
after 8 hours of fasting or after a 120 minute oral 
glucose tolerance test had 75 g glucose blood glucose 
> 140 mg/dL; women breast-feeding; those with co-
morbidities that contribute to the variation in body 
weight such as hyper- and hypothyroidism; chronic 
renal failure and transplant of any organ; use of 
medications that may be related to weight gain and/or 
development of insulin resistance such as the chronic use 
of corticosteroids, antipsychotics, diuretics and statins. 
Patients with hirsutism and/or hyperandrogenism and 
polycystic ovary syndrome were also excluded.
Initially, 49 women were evaluated. Throughout the 
monitoring period, 11 volunteers were excluded either 
for not returning for follow-up or because they became 
pregnant. One participant was excluded from the group 
by initiating physical activity after use of DMPA. At the 
end of the study we evaluated 37 women, 20 from the 
DMPA group and 17 from the IUD group (Figure 1).
This study was approved by the Ethics Committee 
of the Faculty of Medical Sciences – Unicamp, and 
all the volunteers who agreed to participate signed a 
consent form.
Figure 1. Flow chart of the study.
Baseline
(n = 49)
DMPA group
(n = 20)
IUD group
(n = 17)
Excluded for not 
returning for follow-up
(n = 11)
Excluded by initiating 
physical activity after 
use of DMPA
(n = 1)
Anthropometric measurements and body 
composition 
Anthropometric assessment was performed by a single 
examiner. Weight (kg) and height (m) were measured 
using a Welmy mechanical scale with 100 g precision and 
capacity of 200 kg. Height was measured by a stadiometer 
coupled to the scale with a precision of 0.5 cm. Waist 
circumference (WC) was measured with an inelastic 
2 m tape dimension. The anatomical point used was the 
midpoint between the last rib and the iliac crest.
Nutritional status was assessed by calculating the 
BMI, recommended by the World Health Organization 
1995 and 1997 (11).
The percent body fat (% fat), weight, fat mass (FM) 
and fat-free mass (FFM) were assessed by Bioimpedance 
Electric (BIA) using the equipment Biodynamics – 
Bioimpedance Analiser model 310.
Resting energy expenditure
The resting energy expenditure (REE), basal metabolic 
rate (BMR) and substrate used to obtain energy were 
assessed by the indirect calorimetry method. For this, 
a Vmax Encore 29 device coupled to a canopy gas 
exchange was used. 
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The consumption of oxygen (O2) and the 
elimination of carbon dioxide (CO2) in liters per minute 
as well as tidal volume were reported in this procedure. 
From these primary measures, the values  of energy 
expenditure in kilocalories per day were obtained along 
with the respiratory quotient (RQ). The mean values 
obtained in steady state, prefixed as smaller variations 
than 5% in RQ and 10% in CO2 were considered.
Biochemical assays
Serum adiponectin, interleukin (IL) – 6, visfatin, leptin, 
tumor necrosis factor-α (TNF-α), insulin and glucose 
were performed at baseline and after one year of using the 
method. The blood samples were centrifuged, and serum 
was immediately stored in small aliquots in a freezer at 
-80°C. Dosages of adipocytokines and insulin were 
performed in serum by enzyme immunoassay in duplicate 
by enzyme-linked immunosorbent assay (ELISA) using 
commercial kits with high sensitivity and specificity.
Insulin resistance
Homeostasis model assessment of insulin resistance 
(HOMA-IR) was calculated according to the formula: 
fasting insulin (µU/L) x fasting glucose (nmol/L)/22.5. 
Those considered normal values are < 2.7 (12). 
Statistical analysis
All results are expressed as mean ±SD. The Mann-
Whitney test was used to compare the variables between 
two groups. The Wilcoxon test was used for comparison 
of group time fixing. For comparison of numerical 
measurements between times and groups ANOVA was 
used for repeated measurements with transformation 
stations. The significance level for statistical tests was 
5% (P < 0.05). The SAS program for Windows version 
9.2 was used to perform the analyses.
RESULTS
After 12 months of evaluation, we could observe a 
significant increase in the DMPA group in weight 
(61.95 kg ± 9.69 x 64.96 kg ± 9.40, p = 0.0007), 
BMI (23.74 kg/m² ± 3.47 x 24.88 kg/m² ± 3.43, 
p = 0.0007) and body surface (BS) (1.65 ± 0.14 x 
1.69 ± 0.13 p = 0.0148), while the IUD group’s only 
significant increase was observed in the BMI variable 
(24.26 kg/m² ± 2.67 x 24.56 kg/m² ± 2.84, p = 
0.0007) (Table 1).
Relative to REE and RQ, there was an increase of 
BMR in both groups after one year (DMPA group: 
1087.05 kcal/d ± 252.06 x 1319.30 kcal/d ± 133.53, 
p = 0.0027, IUD group: 1187.59 kcal/d ± 246.23 x 
1303.18 kcal/d ± 104.02, p = 0.0027). The RQ was 
significantly reduced after 12 months of study in groups 
DMPA (0.91 x 0.77, p < 0.0001) and IUD (0.87 x 
0.78, p < 0.0001) (Table 2).
Table 3 shows the subdivision of the DMPA group for 
weight gain after 12 months follow-up. The sub-group 
that gained < 3 kg had a significant increase in weight 
(61.24 kg ± 10.38 x 62.51 kg ± 9.95, p = 0.0156), BMI 
(23.44 kg/m² ± 4.25 x 23.93 kg/m² ± 4.15, p = 0.0313) 
and BS (1.64 ± 0.12 x 1.66 ± 0.12 p = 0.0313) with 
RQ reduction (0.87 ± 0.09 x 0.77 ± 0.03, p = 0.0313), 
while the sub-group that gained ≥ 3 kg had a significant 
increase in weight (61.1 kg ± 8.63 x 66.63 kg ± 8.48, 
p = 0.002), BMI (23.47 kg/m² ± 3.50 x 25.55 kg/
m² ± 3.46, p = 0.002), BS (1.64 ± 0.11 x 1.71 ± 0.11, 
p = 0.002), FFM (42.01 kg ± 4.18 x 45.19 kg ± 4.74, 
p = 0.0059), FM (19.14 kg ± 5.26 x 21.44 kg ± 5.82, 
p = 0.0273), BMR (997.70 kcal/d ± 202.72 x 1318.20 
kcal/d ± 157.58, p = 0.0117), Leptin (78.05 ± 76.25 x 
236.86 ± 214.93, p = 0.0195), HOMA-IR (0.70 ± 0.41 
x 1.92 ± 1.41, p = 0.0059) and WC (75.90 cm ± 7.52 
x 79.49 cm ± 7.75, p = 0.002), with RQ significantly 
reduced (0.95 ± 0.12 x 0.77 ± 0.04, p = 0.002). 
Table 1. Characteristics of the DMPA and DIU groups
Variable
Baseline
¥ P value
12 months
¥ P valueDMPA
(n = 20))
Mean ± SD
IUD
(n = 17)
Mean ± SD
DMPA
(n = 20)
Mean ± SD
IUD
(n = 17)
Mean ± SD
Age (years) 29,7 ± 6,2 28,4 ± 5,8 0,4682 _ _
Weight (kg) 61,95 ± 9,69 61,24 ± 6,98 0,5449 64,96* ± 9,40 61,76 ± 7,53 0,0007
BMI (kg/m²) 23,74 ± 3,47 24,26 ± 2,67 0,911 24,88* ± 3,43 24,56** ± 2,84 0,0007
BS 1,65 ± 0,14 1,62 ± 0,09 0,4127 1,69* ± 0,13 1,63 ± 0,10 0,0148
WC (cm) 75,47 ±7,28 77,61 ± 7,88 0,0178 76,74 ± 6,27 75,38 ± 5,66 0,1834
¥: Mann-Whitney test. Statistical significance: p < 0,05. * Depo group difference between baseline and after 12 months. ** DIU group difference between baseline and after 12 months. BS: body 
surface; WC: waist circumference; BMI: body mass index.
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Table 3. Characteristics of DMPA group subdivided by weight gain after12 months
Baseline 12 months
+ P value
Baseline 12 months
+ P value< 3 kg (n = 7) > 3 kg (n = 10)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Weight 61,24 ± 10,38 62,51c ± 9,95 0,0156 61,1 ± 8,63 66,63d ±8,48 0,002
BMI 23,44 ± 4,25 23,93c ± 4,15 0,0313 23,47 ± 3,50 25,55d ± 3,46 0,002
BS 1,64 ± 0,12 1,66c ± 0,12 0,0313 1,64 ± 0,11 1,71d ± 0,11 0,002
% Fat 30,70 ± 5,58 29,30 ± 6,99 0,5625 30,87 ± 4,58 31,76 ± 6,12 0,7891
FFM 42,51 ± 5,32 43,94 ± 6,50 0,1406 42,01 ± 4,18 45,19d ± 4,74 0,0059
FM 19,44 ± 6,07 18,57 ± 6,20 0,7813 19,14 ± 5,26 21,44d ± 5,82 0,0273
BMR 1224,43 ±2 66,82 1334,29 ± 125,04 0,1563 997,70 ± 202,72 1318,20d ± 157,58 0,0117
RQ 0,87 ± 0,09 0,77c ± 0,03 0,0313 0,95 ± 0,12 0,77d ± 0,04 0,002
Adiponectin 10,20 ± 3,21 8,60 ± 4,82 0,375 5,89 ± 1,90 5,96 ± 2,80 0,8457
Leptin 133,53 ± 156,77 174,20 ± 184,10 0,2969 78,05 ± 76,25 236,86d ± 214,93 0,0195
Visfatin 44,78 ± 10,82 45,76 ± 21,36 0,8125 50,68 ± 31,83 43,81 ± 16,23 0,4316
IL-6 1,30 ± 0,42 1,91 ± 1,80 1 1,12 ± 0,77 2,02 ± 2,71 1
TNF-α 4,70 ± 2,11 4,28 ± 3,33 0,2969 4,31 ± 1,98 3,62 ± 1,67 0,1934
HOMA-IR 1,25 ± 1,44 1,15 ± 0,84 0,5781 0,70 ± 0,41 1,92d ± 1,41 0,0059
WC 74,14 ± 8,35 75,67 ± 8,97 0,125 75,90 ± 7,52 79,49d ± 7,75 0,002
+: Wilcoxon test. Statistical significance: p < 0,05. c: Difference sub-group weight gain < 3 kg comparing baseline and after 12 months. d: Difference sub-group weight gain > 3 kg comparing 
baseline and after 12 months.
FFM: free fat mass; FM: fat mass; BMR: basal metabolic rate.
Table 2. Resting energy expenditure and respiratory quotient baseline and after 12 months
Variable
Baseline
¥ P value
12 months
¥ P valueDMPA
(n = 20)
Mean ± SD
IUD
(n = 17)
Mean ± SD
DMPA
(n = 20)
Mean ± SD
IUD
(n = 17)
Mean ± SD
BMR (kcal/d) 1087,05 ± 252,06 1187,59 ± 246,23 0,3674 1319,30* ± 133,53 1303,18** ± 104,02 0,0027
RQ 0,91 ± 0,11 0,87 ± 0,09 0,8134 0,77* ± 0,03 0,78** ± 0,03 < 0,0001
¥: Mann-Whitney test. Statistical significance: p < 0,05. * Difference Depo group between baseline and after 12 months. ** Difference IUD group between baseline and after 12 months. 
RQ: respiratory quotient; BMR: basal metabolic rate.
DISCUSSION
We can consider that our population has a differential in 
relation to other studies evaluating the effect of DMPA, 
considering that our group was paired with the control 
group at baseline for BMI (± 1 kg/m²) and age (± 1 
year), becoming a homogeneous group. Our study 
found that after 12 months of follow-up the injectable 
DMPA users had significant weight gain (3.01 kg). As 
most prospective studies evaluating the effect of DMPA 
were for at least 30 months (6,8,9), we can consider 
that the follow-up period of our study is short compared 
to the others, but we can already observe significant 
changes in important variables studied.
To better assess changes in weight and body 
composition, we made a subdivision of the DMPA 
group for weight gain (< 3 kg and > 3 kg), and observed 
significant changes in weight and body composition in 
both groups, but the group which gained > 3 kg had 
the more pronounced changes. This group had a mean 
gain of 5.53 kg, increased fat mass (2.3 kg) and fat-free 
mass (3.18 kg) after 12 months follow-up. The increase 
in fat-free mass in users of DMPA may be explained by 
the androgenic effect of this contraceptive method (13). 
Berenson and Rahman (9), to compare changes 
in weight and body composition between different 
contraceptive methods, observed at 24 months of 
follow-up an increase of 4.4 kg and after 36 months a 
gain of 5.1 kg in the DMPA group. Of the 5.1 kg that 
the volunteers put on after 36 months, 4.1 kg were of 
fat mass. Moreover, a significant increase in total body 
lean mass after 30 months of follow-up was observed.
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The main contributing factor to the increase in 
body weight after use of DMPA reported in most 
studies is the increase in fat deposits. After 30 months 
of follow-up of users of medroxyprogesterone, Clark 
and cols. (8) observed a gain of 6.1 kg, which is fully 
represented by increased fat mass. There are two other 
possible mechanisms that might explain the weight gain 
associated with DMPA use: the first is its glucocorticoid-
like activity, which appears to be associated with increased 
fat, including visceral fat (14). However, secondly, it is 
also possible that the state of hypoestrogenism induced 
by the injectable may be another factor responsible for 
the increase in weight and body fat (15).
In our study, the subgroup that gained more weight 
at the end of the study also had a significant increase 
in waist circumference and HOMA-IR. Increased 
waist circumference is indicative of an increase in 
subcutaneous and visceral adipose tissue. HOMA-IR, 
although not yet characterized as insulin resistance 
(HOMA-IR > 2.7) in our group, indicates a probable 
trend for the development of insulin resistance with 
increased exposure time for the contraceptive method. 
Accumulation of excess fat can be a critical modulation 
factor for insulin sensitivity, since it promotes the 
release of free fatty acids into the adipocyte circulation 
(16,17). In addition, excess adiposity and adipocyte 
dysfunction result in dysregulation of adipokines, which 
may contribute to the development of various metabolic 
complications through altered glucose and lipid 
homeostasis as well as inflammatory responses (18,19). 
In relation to changes in inflammatory markers, 
we observed a slight decrease in adiponectin levels, 
although it was not significant in the DMPA group. A 
greater reduction in the levels of this marker associated 
with weight gain and increased body fat can contribute 
to the development of insulin resistance. Moreover, 
there was a significant increase in leptin levels in the 
group with greater weight gain. Leptin is directly related 
to body fat in both experimental models and in humans 
(20,21), and is also related to food intake (22). These 
alterations relative to subclinical inflammation agree 
with those present in situations of obesity. The adipose 
tissue contributes to inflammation in both obese 
vascular and non-vascular tissues (23). Abnormal levels 
of fatty acids, lipids, cytokines and activate monocytes 
adipose tissue, increased secretion of inflammatory 
cytokines such as TNF-α, leptin, interleukin (IL)-1, 
IL-6, visfatin and reduced the secretion of anti-
inflammatory cytokine adiponectin (24).
This study also has the important evaluation point 
of resting energy expenditure and respiratory quotient, 
given that data on basal metabolism with DMPA use are 
scarce, only two studies have assessed the resting energy 
expenditure in healthy women using DMPA (25,26). 
The basal metabolic rate increased significantly in the 
DMPA group and control. However, a more significant 
increase in this variable in subgroup DMPA, which 
gained more weight (> 3 kg), can be seen. This increase 
is mainly explained by an increase in fat mass and fat-free 
mass as well. In obese, the resting energy expenditure 
can be influenced mainly by fat-free mass, which is 
the largest contributing factor of variance of the basal 
metabolic rate (50-60%), and fat mass which represents 
(5-6%) of influence on the variation basal metabolic 
rate (27). The respiratory quotient of the two groups 
decreased after 12 months follow-up, indicating a change 
in metabolism of energy substrates. The volunteers at 
baseline had a characteristic respiratory quotient of high 
sugar metabolism but by the end of the study the profile 
changed with lipids starting to metabolize.
This study had the limitation of a small number of 
patients; including more patients could strengthen our 
results. Also we did not evaluate the lipid profile of the 
volunteers.
In conclusion, our study found significant changes 
in weight, body composition and metabolic profile 
of the population studied in the first 12 months of 
contraceptive use. These changes mainly increased 
body weight, leptin levels and HOMA-IR which 
can contribute to the development of some chronic 
complications, including obesity, insulin resistance and 
diabetes mellitus. According to the changes observed 
in our study, we suggest a more careful assessment of 
women who will start using the method as well as those 
who are already using this method of contraception. 
The exposure time method is considered the most 
important factor for the development of these changes. 
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